| Year |
Citation |
Score |
| 2012 |
Claggett B, Lagakos SW, Wang R. Augmented Cross-Sectional Studies with Abbreviated Follow-up for Estimating HIV Incidence Biometrics. 68: 62-74. PMID 21668904 DOI: 10.1111/J.1541-0420.2011.01632.X |
0.35 |
|
| 2010 |
Novitsky V, Wang R, Lagakos S, Essex M. HIV-1 Subtype C Phylodynamics in the Global Epidemic. Viruses. 2: 33-54. PMID 21994599 DOI: 10.3390/V2010033 |
0.337 |
|
| 2010 |
Wang R, Lagakos SW, Gray RJ. Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics (Oxford, England). 11: 676-92. PMID 20439258 DOI: 10.1093/Biostatistics/Kxq021 |
0.378 |
|
| 2010 |
Wang R, Lagakos SW. Augmented cross-sectional prevalence testing for estimating HIV incidence. Biometrics. 66: 864-74. PMID 19912174 DOI: 10.1111/J.1541-0420.2009.01356.X |
0.397 |
|
| 2010 |
Griffin BA, Lagakos SW. Nonparametric inference and uniqueness for periodically observed progressive disease models. Lifetime Data Analysis. 16: 157-75. PMID 19629683 DOI: 10.1007/S10985-009-9122-8 |
0.571 |
|
| 2010 |
Balasubramanian R, Lagakos SW. Estimating HIV incidence based on combined prevalence testing. Biometrics. 66: 1-10. PMID 19397583 DOI: 10.1111/J.1541-0420.2009.01242.X |
0.412 |
|
| 2010 |
Balasubramanian R, Lagakos SW. Correction to article "Estimating HIV incidence based on combined prevalence testing" (Biometrics (2010) 66, (326)) Biometrics. 66: 326. DOI: 10.1111/J.1541-0420.2010.01400.X |
0.343 |
|
| 2009 |
Wang R, Lagakos SW. Inference after variable selection using restricted permutation methods. The Canadian Journal of Statistics = Revue Canadienne De Statistique. 37: 625-644. PMID 20368768 DOI: 10.1002/Cjs.10039 |
0.336 |
|
| 2009 |
Novitsky V, Wang R, Margolin L, Baca J, Kebaabetswe L, Rossenkhan R, Bonney C, Herzig M, Nkwe D, Moyo S, Musonda R, Woldegabriel E, van Widenfelt E, Makhema J, Lagakos S, et al. Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. Plos One. 4: e7727. PMID 19890401 DOI: 10.1371/Journal.Pone.0007727 |
0.324 |
|
| 2009 |
Wang R, Lagakos SW. On the use of adjusted cross-sectional estimators of HIV incidence. Journal of Acquired Immune Deficiency Syndromes (1999). 52: 538-47. PMID 19881357 DOI: 10.1097/Qai.0B013E3181C080A7 |
0.333 |
|
| 2009 |
Hu XJ, Lagakos SW, Lockhart RA. Marginal analysis of panel counts through estimating functions. Biometrika. 96: 445-456. PMID 19543426 DOI: 10.1093/Biomet/Asp010 |
0.327 |
|
| 2009 |
Novitsky V, Wang R, Kebaabetswe L, Greenwald J, Rossenkhan R, Moyo S, Musonda R, Woldegabriel E, Lagakos S, Essex M. Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. Journal of Acquired Immune Deficiency Syndromes (1999). 52: 265-72. PMID 19525854 DOI: 10.1097/Qai.0B013E3181Ab6Ef0 |
0.4 |
|
| 2009 |
Novitsky V, Woldegabriel E, Kebaabetswe L, Rossenkhan R, Mlotshwa B, Bonney C, Finucane M, Musonda R, Moyo S, Wester C, van Widenfelt E, Makhema J, Lagakos S, Essex M. Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. Journal of Acquired Immune Deficiency Syndromes (1999). 50: 65-76. PMID 19295336 DOI: 10.1097/Qai.0B013E3181900141 |
0.346 |
|
| 2009 |
Zhao L, Hu XJ, Lagakos SW. Statistical monitoring of clinical trials with multivariate response and/or multiple arms: a flexible approach. Biostatistics (Oxford, England). 10: 310-23. PMID 19015160 DOI: 10.1093/Biostatistics/Kxn037 |
0.348 |
|
| 2009 |
Novitsky V, Lagakos S, Herzig M, Bonney C, Kebaabetswe L, Rossenkhan R, Nkwe D, Margolin L, Musonda R, Moyo S, Woldegabriel E, van Widenfelt E, Makhema J, Essex M. Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology. 383: 47-59. PMID 18973914 DOI: 10.1016/J.Virol.2008.09.017 |
0.323 |
|
| 2008 |
Lagakos SW, Gable AR. Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. The New England Journal of Medicine. 358: 1543-5. PMID 18403764 DOI: 10.1056/Nejmp0802028 |
0.316 |
|
| 2008 |
Griffin BA, Lagakos SW. Design and analysis of arm-in-cage experiments: inference for three-state progressive disease models with common periodic observation times. Biometrics. 64: 337-44. PMID 17970816 DOI: 10.1111/J.1541-0420.2007.00926.X |
0.568 |
|
| 2008 |
Zhang P, Lagakos SW. Analysis of time to a silent event whose occurrence is monitored with error, with application to mother-to-child HIV transmission. Statistics in Medicine. 27: 4637-46. PMID 17960778 DOI: 10.1002/Sim.3125 |
0.42 |
|
| 2007 |
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. The New England Journal of Medicine. 357: 2189-94. PMID 18032770 DOI: 10.1056/Nejmsr077003 |
0.306 |
|
| 2007 |
Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, ... Lagakos S, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. The New England Journal of Medicine. 356: 135-47. PMID 17215531 DOI: 10.1056/Nejmoa062876 |
0.331 |
|
| 2007 |
Hu XJ, Lagakos SW. Nonparametric estimation of the mean function of a stochastic process with missing observations. Lifetime Data Analysis. 13: 51-73. PMID 17195105 DOI: 10.1007/S10985-006-9030-0 |
0.346 |
|
| 2007 |
Kang M, Lagakos SW. Statistical methods for panel data from a semi-Markov process, with application to HPV. Biostatistics (Oxford, England). 8: 252-64. PMID 16740624 DOI: 10.1093/Biostatistics/Kxl006 |
0.524 |
|
| 2006 |
Tian L, Lagakos S. Analysis of a partially observed binary covariate process and a censored failure time in the presence of truncation and competing risks. Biometrics. 62: 821-828. PMID 16984325 DOI: 10.1111/J.1541-0420.2006.00530.X |
0.316 |
|
| 2006 |
Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, Gilbert PB, Stevens L, Peter T, Kim S, van Widenfelt E, Moffat C, Ndase P, Arimi P, Kebaabetswe P, ... ... Lagakos S, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. Jama. 296: 794-805. PMID 16905785 DOI: 10.1001/Jama.296.7.794 |
0.305 |
|
| 2006 |
Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, Stevens L, Heymann SJ, Ndung'u T, Gaseitsiwe S, Novitsky V, Makhema J, Lagakos S, Essex M. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. Aids (London, England). 20: 1281-8. PMID 16816557 DOI: 10.1097/01.Aids.0000232236.26630.35 |
0.321 |
|
| 2006 |
Lagakos SW. Time-to-event analyses for long-term treatments--the APPROVe trial. The New England Journal of Medicine. 355: 113-7. PMID 16801354 DOI: 10.1056/Nejmp068137 |
0.323 |
|
| 2006 |
Griffin BA, Lagakos S. Analysis of failure time data arising from studies with alternating treatment schedules Journal of the American Statistical Association. 101: 510-520. DOI: 10.1198/016214505000000880 |
0.57 |
|
| 2004 |
Li QH, Lagakos SW. Comparisons of test statistics arising from marginal analyses of multivariate survival data. Lifetime Data Analysis. 10: 389-405. PMID 15690992 DOI: 10.1007/0-387-26023-4_20 |
0.399 |
|
| 2004 |
Kang M, Lagakos SW. Evaluation of log-rank tests for infrequent observations from a multi-state process, with application to HPV vaccine efficacy. Statistics in Medicine. 23: 3681-96. PMID 15534891 DOI: 10.1002/Sim.1916 |
0.521 |
|
| 2004 |
Balasubramanian R, Lagakos SW. Analyzing time-to-event data in a clinical trial when an unknown proportion of subjects has experienced the event at entry. Biometrics. 60: 335-43. PMID 15180658 DOI: 10.1111/J.0006-341X.2004.00177.X |
0.415 |
|
| 2004 |
Kang M, Lagakos SW. Evaluating the role of human papillomavirus vaccine in cervical cancer prevention. Statistical Methods in Medical Research. 13: 139-55. PMID 15068258 DOI: 10.1191/0962280204Sm358Ra |
0.488 |
|
| 2004 |
Cheng DM, Lagakos SW. Covariate analysis of viral eradication studies. Biostatistics (Oxford, England). 1: 329-40. PMID 12933513 DOI: 10.1093/Biostatistics/1.3.329 |
0.393 |
|
| 2003 |
Cheng DM, Lagakos SW. Use of incomplete post-treatment data in the analysis of viral eradication studies. Statistics in Medicine. 22: 3611-28. PMID 14652864 DOI: 10.1002/Sim.1587 |
0.376 |
|
| 2003 |
Balasubramanian R, Lagakos SW. Estimation of a failure time distribution based on imperfect diagnostic tests Biometrika. 90: 171-182. DOI: 10.1093/Biomet/90.1.171 |
0.411 |
|
| 2002 |
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. The Journal of Infectious Diseases. 186: 626-33. PMID 12195349 DOI: 10.1086/342681 |
0.372 |
|
| 2001 |
Balasubramanian R, Lagakos SW. Estimation of the timing of perinatal transmission of HIV. Biometrics. 57: 1048-58. PMID 11764243 DOI: 10.1111/J.0006-341X.2001.01048.X |
0.423 |
|
| 2001 |
Glidden D, Kim S, Lagakos S. Effectiveness of Remune Clinical and Vaccine Immunology. 8: 468-469. PMID 11324587 DOI: 10.1128/Cdli.8.2.468-469.2001 |
0.338 |
|
| 2001 |
Weinberg JM, Lagakos SW. Efficiency comparisons of rank and permutation tests based on summary statistics computed from repeated measures data Statistics in Medicine. 20: 705-731. PMID 11241572 DOI: 10.1002/Sim.708 |
0.379 |
|
| 2001 |
Dirienzo AG, Lagakos SW. Bias correction for score tests arising from misspecified proportional hazards regression models Biometrika. 88: 421-434. DOI: 10.1093/Biomet/88.2.421 |
0.331 |
|
| 2001 |
Weinberg JM, Lagakos SW. Linear rank tests under general alternatives, with application to summary statistics computed from repeated measures data Journal of Statistical Planning and Inference. 96: 109-127. DOI: 10.1016/S0378-3758(00)00328-1 |
0.331 |
|
| 2000 |
Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. Jama. 284: 2193-202. PMID 11056590 DOI: 10.1001/Jama.284.17.2193 |
0.363 |
|
| 2000 |
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359 Journal of Infectious Diseases. 182: 1375-1384. PMID 11023461 DOI: 10.1086/315867 |
0.364 |
|
| 2000 |
Cheng DM, Lagakos SW. The one-sample problem from eradication studies of chronic viral infections Biometrics. 56: 626-633. PMID 10877327 DOI: 10.1111/J.0006-341X.2000.00626.X |
0.35 |
|
| 2000 |
Dixon DO, Lagakos SW. Should data and safety monitoring boards share confidential interim data? Controlled Clinical Trials. 21: 1-6. PMID 10659999 DOI: 10.1016/S0197-2456(99)00042-2 |
0.319 |
|
| 2000 |
Weinberg JM, Lagakos SW. Asymptotic Behavior of Linear Permutation Tests under General Alternatives, with Application to Test Selection and Study Design Journal of the American Statistical Association. 95: 596-607. DOI: 10.1080/01621459.2000.10474235 |
0.33 |
|
| 1999 |
Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. Jama. 282: 2305-12. PMID 10612317 DOI: 10.1001/Jama.282.24.2305 |
0.339 |
|
| 1999 |
Hu XJ, Lagakos SW. Group sequential analyses for the mean function of a repeated measure process Statistics in Medicine. 18: 2287-2299. PMID 10474139 DOI: 10.1002/(Sici)1097-0258(19990915/30)18:17/18<2287::Aid-Sim255>3.0.Co;2-D |
0.358 |
|
| 1999 |
Joan Hu X, Lagakos SW. Interim analyses using repeated confidence bands Biometrika. 86: 517-529. DOI: 10.1093/Biomet/86.3.517 |
0.336 |
|
| 1997 |
Li QHL, Lagakos SW. Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event Statistics in Medicine. 16: 925-940. PMID 9160489 DOI: 10.1002/(Sici)1097-0258(19970430)16:8<925::Aid-Sim545>3.0.Co;2-2 |
0.342 |
|
| 1996 |
Kim HM, Lagakos SW. Non-parametric inference of a failure time distribution when the failure times are estimated Statistics in Medicine. 15: 2475-2490. PMID 8931214 DOI: 10.1002/(Sici)1097-0258(19961130)15:22<2475::Aid-Sim465>3.0.Co;2-X |
0.322 |
|
| 1996 |
Elashoff M, Lagakos S. HIV treatment strategies utilizing virologic and immunologic markers as criteria for changing treatments. Statistics in Medicine. 15: 2425-2443. PMID 8931211 DOI: 10.1002/(Sici)1097-0258(19961130)15:22<2425::Aid-Sim461>3.0.Co;2-D |
0.323 |
|
| 1995 |
Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. The New England Journal of Medicine. 333: 401-7. PMID 7616988 DOI: 10.1056/Nejm199508173330701 |
0.357 |
|
| 1995 |
Kim HM, Lagakos SW. Estimation of individual and population noncompliance using longitudinal marker data, with application to aids Therapeutic Innovation &Amp; Regulatory Science. 29: 1601S-1614S. DOI: 10.1177/00928615950290S108 |
0.383 |
|
| 1994 |
Gomez G, Lagakos SW. Estimation of the infection time and latency distribution of AIDS with doubly censored data Biometrics. 50: 204-212. PMID 8086603 DOI: 10.2307/2533210 |
0.398 |
|
| 1994 |
Kim HM, Lagakos SW. Assessing drug compliance using longitudinal marker data, with application to AIDS Statistics in Medicine. 13: 2141-2153. PMID 7846416 DOI: 10.1002/Sim.4780131921 |
0.377 |
|
| 1993 |
Choi S, Lagakos SW, Schooley RT, Volberding PA. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine Annals of Internal Medicine. 118: 674-680. PMID 8096373 DOI: 10.7326/0003-4819-118-9-199305010-00003 |
0.338 |
|
| 1993 |
Lagakos SW. Surrogate Markers in AIDS Clinical Trials: Conceptual Basis, Validation, and Uncertainties Clinical Infectious Diseases. 16: S22-S25. PMID 8093844 DOI: 10.1093/Clinids/16.Supplement_1.S22 |
0.391 |
|
| 1993 |
Dawson JD, Lagakos SW. Size and power of two-sample tests of repeated measures data Biometrics. 49: 1022-1032. PMID 7906957 DOI: 10.2307/2532244 |
0.376 |
|
| 1993 |
Begg MD, Lagakos S. Loss in Efficiency Caused by Omitting Covariates and Misspecifying Exposure in Logistic Regression Models Journal of the American Statistical Association. 88: 166-170. DOI: 10.1080/01621459.1993.10594307 |
0.323 |
|
| 1992 |
Koch MA, Volberding PA, Lagakos SW, Booth DK, Pettinelli C, Myers MW. Toxic Effects of Zidovudine in Asymptomatic Human Immunodeficiency Virus-Infected Individuals With CD4<R>+</R> Cell Counts of 0.50×10<R>9</R>/L or Less: Detailed and Updated Results From Protocol 019 of the AIDS Clinical Trials Group Archives of Internal Medicine. 152: 2286-2292. PMID 1359846 DOI: 10.1001/Archinte.1992.00400230094016 |
0.315 |
|
| 1992 |
Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. The New England Journal of Medicine. 327: 581-7. PMID 1353607 DOI: 10.1056/Nejm199208273270901 |
0.384 |
|
| 1992 |
Lagakos SW, Hoth DF. Surrogate markers in AIDS: Where are we? Where are we going? Annals of Internal Medicine. 116: 599-601. PMID 1347443 DOI: 10.7326/0003-4819-116-7-599 |
0.367 |
|
| 1992 |
Begg MD, Lagakos S. Effects of Mismodeling on Tests of Association Based on Logistic Regression Models The Annals of Statistics. 20: 1929-1952. DOI: 10.1214/Aos/1176348896 |
0.323 |
|
| 1991 |
Lagakos S, Fischl MA, Stein DS, Lim L, Volberding P. Effects of Zidovudine Therapy in Minority and Other Subpopulations With Early HIV Infection Jama: the Journal of the American Medical Association. 266: 2709-2712. PMID 1942422 DOI: 10.1001/Jama.1991.03470190057029 |
0.333 |
|
| 1990 |
Lagakos SW, Lim LLY, Robins JM. Adjusting for early treatment termination in comparative clinical trials Statistics in Medicine. 9: 1417-1424. PMID 2281229 DOI: 10.1002/Sim.4780091204 |
0.344 |
|
| 1990 |
Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Gruttola V, Finkelstein DM, Gatsonis C, Gelber RD, Lagakos S. Design considerations for AIDS trials. The New England Journal of Medicine. 323: 1343-8. PMID 2215622 DOI: 10.1056/Nejm199011083231912 |
0.314 |
|
| 1990 |
Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. The New England Journal of Medicine. 322: 941-9. PMID 1969115 DOI: 10.1056/Nejm199004053221401 |
0.377 |
|
| 1990 |
Kim MY, Lagakos SW. Estimating the infectivity of HIV from partner studies Annals of Epidemiology. 1: 117-128. PMID 1669741 DOI: 10.1016/1047-2797(90)90003-B |
0.409 |
|
| 1989 |
De Gruttola V, Lagakos SW. The value of AIDS incidence data in assessing the spread of HIV infection Statistics in Medicine. 8: 35-43. PMID 2919246 DOI: 10.1002/Sim.4780080106 |
0.383 |
|
| 1989 |
De Gruttola V, Lagakos SW. Analysis of doubly-censored survival data, with application to AIDS Biometrics. 45: 1-11. PMID 2497809 DOI: 10.2307/2532030 |
0.413 |
|
| 1988 |
Lagakos SW, Barraj LM, Gruttola VD. Nonparametric analysis of truncated survival data, with application to aids Biometrika. 75: 515-523. DOI: 10.1093/Biomet/75.3.515 |
0.389 |
|
| 1981 |
Lagakos S, Mosteller F. A case study of statistics in the regulatory process: the FD&C Red No. 40 experiments. Journal of the National Cancer Institute. 66: 197-212. PMID 6935460 DOI: 10.1093/Jnci/66.1.197 |
0.304 |
|
| 1981 |
Lagakos SW. The graphical evaluation of explanatory variables in proportional hazard regression models Biometrika. 68: 93-98. DOI: 10.1093/Biomet/68.1.93 |
0.306 |
|
| 1981 |
Lagakos SW, Reid N. Estimating convolutions from partially censored data Biometrika. 68: 113-117. DOI: 10.1093/Biomet/68.1.113 |
0.328 |
|
| 1977 |
Lagakos SW. Using auxiliary variables for improved estimates of survival time Biometrics. 33: 399-404. PMID 884198 DOI: 10.2307/2529792 |
0.324 |
|
| 1976 |
Lagakos SW. A stochastic model for censored survival data in the presence of an auxiliary variable Biometrics. 32: 551-559. PMID 963170 DOI: 10.2307/2529744 |
0.343 |
|
| Show low-probability matches. |